_2020091018165303jzv.jpg "Decoding The World Of ETF")
Oct 28, 2020 01:19 PM IST Motilal Oswal is bullish on Aurobindo Pharma recommended buy rating on the stock with a target price of Rs 985 in its research report dated October 26, 2020.
Oct 27, 2020 02:00 PM IST ICICI Direct is bullish on Aurobindo Pharma recommended buy rating on the stock with a target price of Rs 1025 in its research report dated October 26, 2020.
Oct 27, 2020 09:24 AM IST The Natrol sale will help Aurobindo Pharma focus on the core generic drug and injectable businesses
Oct 26, 2020 10:34 AM IST Jefferies served as the sole financial adviser and Sullivan & Cromwell LLP acted as legal counsel to Aurobindo.
Sep 28, 2020 11:22 PM IST Motilal Oswal is bullish on Aurobindo Pharma recommended buy rating on the stock with a target price of Rs 1030 in its research report dated September 27, 2020.
Sep 23, 2020 12:14 PM IST Sharekhan is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 975 in its research report dated September 22, 2020.
Sep 16, 2020 09:40 AM IST Vaccine capacity creation puts Aurobindo in the league of Serum Institute of India and Cadila in the race for a Covid drug
Sep 15, 2020 06:35 PM IST Aurobindo Pharma said it is developing a vaccine for COVID-19 through its wholly-owned US subsidiary, Auro Vaccines.
Aug 19, 2020 11:07 AM IST KR Choksey is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 1027 in its research report dated August 17, 2020.
Aug 17, 2020 05:06 PM IST Emkay Global Financial is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 1000 in its research report dated August 13, 2020.
Aug 16, 2020 09:08 AM IST Prabhudas Lilladher recommended Hold rating on Aurobindo Pharma with a target price of Rs 838 in its research report dated August 13, 2020.
Aug 16, 2020 07:21 AM IST Sharekhan recommended Hold rating on Aurobindo Pharma with a target price of Rs 975 in its research report dated August 13, 2020.
Aug 16, 2020 07:20 AM IST Motilal Oswal is bullish on Aurobindo Pharma recommended buy rating on the stock with a target price of Rs 1055 in its research report dated August 13, 2020.
Aug 14, 2020 12:22 PM IST Aurobindo is building capacities for emerging drug delivery systems in the US and could be a key beneficiary of the localisation initiative there
Aug 14, 2020 12:22 PM IST ICICI Direct is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 1100 in its research report dated August 13, 2020.
Aug 13, 2020 09:51 AM IST At operating level, its earnings before interest, tax, depreciation and amortisation (EBITDA) rose 9.7 percent YoY to Rs 1,257.4 crore, and margin expanded 10 bps to 21.2 percent in Q1FY21, compared to same period last year.
Aug 12, 2020 09:19 PM IST Revenue from operations for the quarter under review at Rs 5,924.8 crore increased by 8.8 percent YoY, with US formulation business showing a 15.6 percent growth at Rs 3,107.1 crore
Aug 07, 2020 08:22 AM IST Experts are of the view that investors should trade with caution, and a more sustainable move can be seen only a close above 11225. Immediate support is placed at 11,100 levels.
Jul 09, 2020 10:10 AM IST The stock, which has surged 86 percent in the last three months, hitting a new high of Rs 821.90.
Jul 08, 2020 11:00 AM IST The brokerage now expects Nifty earnings to grow at a CAGR of 16 percent over FY20-22, albeit on a low base and values the Nifty at 10,300 i.e. 1.2x PEG on FY22E EPS of Rs 543 with corresponding Sensex target placed at 34,800.
Jun 25, 2020 03:05 PM IST The four stocks that were winners in last 3 series were M&M, Vodafone Idea, Balkrishna Industries and Aurobindo Pharma
Jun 25, 2020 03:00 PM IST The firm is developing eight inhalers and six nasal sprays, out of which two products have already been filed, Aurobindo Pharma Managing Director N Govindarajan said in an analyst call.
Jun 12, 2020 08:20 AM IST Attorney General Brian E Frosh in a statement issued on Wednesday said the new complaint, filed in the U.S. District Court for the District of Connecticut, focuses on 80 topical generic drugs that account for billions of dollars of sales in the United States and the complaint names 26 corporate defendants and 10 individual defendants.
Jun 07, 2020 08:50 PM IST Emkay Global Financial is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 835 in its research report dated June 04, 2020.
Jun 07, 2020 08:36 PM IST Motilal Oswal is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 880 in its research report dated June 04, 2020.
